<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Blood Adv</journal-id>
        <journal-id journal-id-type="iso-abbrev">Blood Adv</journal-id>
        <journal-id journal-id-type="pmc-domain-id">3318</journal-id>
        <journal-id journal-id-type="pmc-domain">bloodadv</journal-id>
        <journal-title-group>
          <journal-title>Blood Advances</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">2473-9529</issn>
        <issn pub-type="epub">2473-9537</issn>
        <publisher>
          <publisher-name>The American Society of Hematology</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC10875331</article-id>
        <article-id pub-id-type="pmcid-ver">PMC10875331.1</article-id>
        <article-id pub-id-type="pmcaid">10875331</article-id>
        <article-id pub-id-type="pmcaiid">10875331</article-id>
        <article-id pub-id-type="pmid">38147626</article-id>
        <article-id pub-id-type="doi">10.1182/bloodadvances.2023011262</article-id>
        <article-id pub-id-type="pii">S2473-9529(23)00714-0</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Myeloid Neoplasia</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer<sup><xref ref-type="fn" rid="d35e77">∗</xref></sup><sup><xref ref-type="fn" rid="d35e81">†</xref></sup></article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" id="au1">
            <name name-style="western">
              <surname>Stonestrom</surname>
              <given-names initials="AJ">Aaron J.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au2">
            <name name-style="western">
              <surname>Menghrajani</surname>
              <given-names initials="KN">Kamal N.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au3">
            <name name-style="western">
              <surname>Devlin</surname>
              <given-names initials="SM">Sean M.</given-names>
            </name>
            <xref rid="aff3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author" id="au4">
            <name name-style="western">
              <surname>Franch-Expósito</surname>
              <given-names initials="S">Sebastià</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author" id="au5">
            <name name-style="western">
              <surname>Ptashkin</surname>
              <given-names initials="RN">Ryan N.</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author" id="au6">
            <name name-style="western">
              <surname>Patel</surname>
              <given-names initials="SY">Swara Y.</given-names>
            </name>
            <xref rid="aff5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author" id="au7">
            <name name-style="western">
              <surname>Spitzer</surname>
              <given-names initials="B">Barbara</given-names>
            </name>
            <xref rid="aff6" ref-type="aff">6</xref>
          </contrib>
          <contrib contrib-type="author" id="au8">
            <name name-style="western">
              <surname>Wu</surname>
              <given-names initials="X">Xiaodi</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au9">
            <name name-style="western">
              <surname>Jee</surname>
              <given-names initials="J">Justin</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author" id="au10">
            <name name-style="western">
              <surname>Sánchez Vela</surname>
              <given-names initials="P">Pablo</given-names>
            </name>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au11">
            <name name-style="western">
              <surname>Milbank</surname>
              <given-names initials="JH">Jennifer H.</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author" id="au12">
            <name name-style="western">
              <surname>Shah</surname>
              <given-names initials="RH">Ronak H.</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author" id="au13">
            <name name-style="western">
              <surname>Mohanty</surname>
              <given-names initials="AS">Abhinita S.</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author" id="au14">
            <name name-style="western">
              <surname>Brannon</surname>
              <given-names initials="AR">A. Rose</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author" id="au15">
            <name name-style="western">
              <surname>Xiao</surname>
              <given-names initials="W">Wenbin</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author" id="au16">
            <name name-style="western">
              <surname>Berger</surname>
              <given-names initials="MF">Michael F.</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author" id="au17">
            <name name-style="western">
              <surname>Mantha</surname>
              <given-names initials="S">Simon</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author" id="au18">
            <name name-style="western">
              <surname>Levine</surname>
              <given-names initials="RL">Ross L.</given-names>
            </name>
            <email>leviner@mskcc.org</email>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
            <xref rid="cor1" ref-type="corresp">∗</xref>
          </contrib>
          <aff id="aff1"><label>1</label>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff2"><label>2</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff3"><label>3</label>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff4"><label>4</label>Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff5"><label>5</label>Hunter College, New York, NY</aff>
          <aff id="aff6"><label>6</label>Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        </contrib-group>
        <author-notes>
          <corresp id="cor1"><label>∗</label>Correspondence: Ross L. Levine, Rockefeller Research Labs, 430 E 67th St, 4th floor, New York, NY 10065; <email>leviner@mskcc.org</email></corresp>
        </author-notes>
        <pub-date pub-type="collection">
          <day>27</day>
          <month>2</month>
          <year>2024</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>28</day>
          <month>12</month>
          <year>2023</year>
        </pub-date>
        <volume>8</volume>
        <issue>4</issue>
        <issue-id pub-id-type="pmc-issue-id">456048</issue-id>
        <fpage>846</fpage>
        <lpage>856</lpage>
        <history>
          <date date-type="received">
            <day>19</day>
            <month>7</month>
            <year>2023</year>
          </date>
          <date date-type="accepted">
            <day>20</day>
            <month>11</month>
            <year>2023</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>28</day>
              <month>12</month>
              <year>2023</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>19</day>
              <month>02</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-02-20 14:25:10.000">
              <day>20</day>
              <month>02</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</copyright-statement>
          <copyright-year>2024</copyright-year>
          <copyright-holder>The American Society of Hematology</copyright-holder>
          <license>
            <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
            <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/>
        <abstract abstract-type="author-highlights" id="abs0010">
          <title>Key Points</title>
          <p>
            <list list-type="simple" id="ulist0010">
              <list-item id="u0010">
                <label>•</label>
                <p id="p0010">High-risk CH mutations in <italic toggle="yes">JAK2</italic>, <italic toggle="yes">RUNX1</italic>, and <italic toggle="yes">XPO1</italic> anticipate hematologic malignancy in patients with cancer.</p>
              </list-item>
              <list-item id="u0015">
                <label>•</label>
                <p id="p0015">Functionally neutral silent CH variants are significant predictors of hematologic malignancy risk.</p>
              </list-item>
            </list>
          </p>
        </abstract>
        <abstract abstract-type="graphical" id="abs0015">
          <title>Visual Abstract</title>
          <fig id="undfig1" position="anchor" orientation="portrait">
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-011262-ga1.jpg"/>
          </fig>
        </abstract>
        <abstract id="abs0020">
          <title>Abstract</title>
          <p>Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) ≥ 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy, we analyzed data from 42 714 patients who underwent blood sequencing as a normal comparator for nonhematologic tumor testing using a large cancer-related gene panel. We cataloged hematologic malignancies in this cohort using natural language processing and manual curation of medical records. We found that some CH genotypes including <italic toggle="yes">JAK2</italic>, <italic toggle="yes">RUNX1</italic>, and <italic toggle="yes">XPO1</italic> variants were associated with high hematologic malignancy risk. Chronic disease was predicted better than acute disease suggesting the influence of length bias. To better understand the implications of hematopoietic clonality independent of mutational function, we evaluated a set of silent synonymous and noncoding mutations. We found that silent CH, particularly when multiple variants were present or VAF was high, was associated with increased risk of hematologic malignancy. We tracked expansion of CH mutations in 26 hematologic malignancies sequenced with the same platform. <italic toggle="yes">JAK2</italic> and <italic toggle="yes">TP53</italic> VAF consistently expanded at disease onset, whereas <italic toggle="yes">DNMT3A</italic> and silent CH VAFs mostly decreased. These data inform the clinical and biological interpretation of CH in the context of nonhematologic cancer.</p>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="sec1">
        <title>Introduction</title>
        <p id="p0020">Clonal hematopoiesis (CH) is commonly defined as the presence of a somatic mutation in the blood or bone marrow with a variant allele frequency (VAF) of at least ∼2%.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref> CH has been associated with hematologic malignancy risk in diverse cohorts despite methodologic variability, including mutations that are counted and the range of VAFs considered.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref> Mutations in <italic toggle="yes">DNMT3A</italic>, <italic toggle="yes">TET2</italic>, and <italic toggle="yes">ASXL1</italic> are highly prevalent across studies and have been validated as leukemia drivers in experimental models.<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref> The driver status of many other mutations has not been directly tested and must be inferred based on function in hematologic malignancy and/or enrichment of nonsynonymous mutations relative to synonymous mutations (dN/dS), suggesting active clonal selection.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></p>
        <p id="p0025">Analysis of population-based whole-exome and whole-genome sequencing studies has built the foundation of modern CH science.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> In these studies, CH calls are filtered to putative disease genes, and, often, higher VAF thresholds are used because of noise accompanying the large number of genes examined and limited sequencing depth. Unfortunately, the relatively limited benefit of identifying modest absolute increases in risk of malignancy has been a challenge to real-world use of CH information. Two recent analyses of UK Biobank data address this by focusing on a small number of high-risk CH genes and incorporating other hematologic parameters into risk models.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> These studies are a significant step forward in understanding the risk posed by CH in healthy individuals.</p>
        <p id="p0030">Most mutations in hematopoietic cells occur stochastically and are functionally neutral. Indeed, the mutational fingerprints of hematopoietic stem and progenitor cells has been used to construct elegant lineage hierarchies in extensively sequenced individuals.<xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref> Sequencing error and pervasive age-related hematopoietic oligoclonality complicate use of apparently neutral genetic information. Some authors have addressed this through definition of CH with unknown drivers (CH-UD), which requires identification of multiple neutral variants at high VAF (&gt;10%) in the whole-genome or whole-exome context.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> CH-UD correlates with subsequent hematologic malignancy and death, suggesting that CH can predict risk even in the absence of pathologic mutational function.</p>
        <p id="p0035">CH is an increasingly common discovery in patients with solid organ tumors because of the expanding use of sequencing-based diagnostics. The leukemic potential of CH has salience in this setting because these patients are often treated with genotoxic chemotherapy which also increases their risk of hematologic neoplasm.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Conceptually, therapy-related hematologic neoplasms can be directly caused by drug-induced mutagenesis, because when a topoisomerase inhibitor induces chromosomal translocations, or indirectly caused by favoring expansion of preleukemic clones, for example those with <italic toggle="yes">TP53</italic> loss. Work from our center and others has reported that CH poses an increased hematologic malignancy risk in this context.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> The extent to which this risk varies based on leukemogenic mechanism is unknown.</p>
        <p id="p0040">To better understand the association of CH genotype and hematologic malignancy, we expanded the Memorial Sloan Kettering (MSK)-IMPACT CH cohort to include 42 714 patients. We annotated this cohort using a hybrid manual or computational pipeline to comprehensively identify hematologic malignancy events. Combining these datasets allowed us to examine CH in the context of cancer at a more granular level than was previously possible. We report using this data to identify CH genotypes associated with risk of hematologic malignancy and evaluate the hematologic malignancies best predicted by CH.</p>
      </sec>
      <sec id="sec2">
        <title>Methods</title>
        <sec id="sec2.1">
          <title>Patient selection and record review</title>
          <p id="p0045">This study was approved by the MSK Cancer Center Institutional Review Board, and all patients provided informed consent for tumor and normal sequencing and review of their electronic medical record. We used a natural language processing pipeline (Clinical Event Detection and Recording System; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cedars.io" id="intref0015">https://cedars.io</ext-link>) to identify medical records potentially referencing hematopoietic disease. The identified EMR portions were manually curated by trained annotators (Vasta Global, New York, NY) to make initial diagnoses. Initial diagnoses were confirmed by at least 1 American Board of Internal Medicine–certified hematologist or oncologist to generate a set of final diagnoses.</p>
        </sec>
        <sec id="sec2.2">
          <title>Sequencing and data processing</title>
          <p id="p0050">The presence of CH was determined by peripheral-blood sequencing using the MSK-IMPACT platform (IMPACT).<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> IMPACT is an oligonucleotide hybridization capture–based next-generation targeted sequencing assay developed for cancer genomic profiling. Matched normal blood samples were collected with consent from patients and evaluated for mutations across nearly all exons of between 341 and 505 genes depending on assay version (<xref rid="appsec1" ref-type="sec">supplemental Table 1</xref>). Sequencing of matched normal blood samples was used for CH calling, as previously described.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> In brief, the Mutect and VarDict algorithms were used to call single-nucleotide variants, and insertions or deletions were called using VarDict and Somatic Indel Detector. Variants were retained if identified by 2 callers. Postprocessing filters were used to remove putative sequencing artifacts and germ line polymorphisms before data interpretation. Conventional CH variants were defined as nonsynonymous variants in exons and mutations with a predicted impact on splicing. Silent CH variants were synonymous variants in coding regions and nonsplice site noncoding variants. Mosaic chromosome alterations were identified using FACETS-CH, as previously described.<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref></p>
        </sec>
        <sec id="sec2.3">
          <title>Statistical analysis</title>
          <p id="p0055">Descriptive analyses and data visualization were performed in R version 4.1. The day of the blood draw procedure was considered day 0 in all analyses. Statistical models evaluating CH estimated subdistribution hazard ratio (HR) for the risk of hematologic malignancy with Fine and Gray competing risk regression using R package cmprsk. Death was included as a competing risk, and these models were adjusted for gender, solid cancer type, and age using a penalized spline. The analysis of gene-specific hazard rate was performed using cause-specific Cox regression with Firth penalized likelihood using R package coxphf. These models were adjusted for gender, solid cancer type, and age using a polynomial spline.</p>
          <p id="p0060">We used the R package dndscv to calculate the ratio of observed to expected nonsynonymous variants per synonymous variant in a regression model using both local and global mutation rates as covariates.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></p>
        </sec>
      </sec>
      <sec id="sec3">
        <title>Results</title>
        <sec id="sec3.1">
          <title>Clonal hematopoiesis in 42 714 patients with nonhematologic malignancies</title>
          <p id="p0065">We assessed variants in at least 341 genes in MSK IMPACT sequencing for 42 714 patients, of whom 39 510 were alive with no hematologic diagnosis within 2 weeks and had medical record follow up beyond this time (<xref rid="fig1" ref-type="fig">Figure 1</xref>A). A total of 11 735 patients had at least 1 conventional CH variant in a cancer-related gene (29.7%), including 3871 with ≥2 variants (<xref rid="appsec1" ref-type="sec">supplemental Figure 1</xref>). The most common CH mutations were in <italic toggle="yes">DNMT3A</italic>, <italic toggle="yes">TET2</italic>, and <italic toggle="yes">ASXL1</italic> as well as genes related to DNA damage response, including <italic toggle="yes">PPM1D</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">TP53</italic> (<xref rid="fig1" ref-type="fig">Figure 1</xref>B). We also identified mosaic copy number changes in 675 patients (1.9%) out of 35 134 evaluable among the cohort (<xref rid="fig1" ref-type="fig">Figure 1</xref>C; <xref rid="appsec1" ref-type="sec">supplemental Figure 2</xref>).<fig id="fig1" position="float" orientation="portrait"><label>Figure 1.</label><caption><p><bold>Clonal hematopoiesis in 42 714 patients with nonhematologic cancer assessed for CH.</bold> (A) Restriction of full cohort of 42 714 patients to those living at least 2 weeks, followed at least 2 weeks, and not yet diagnosed with a hematologic malignancy for at least 2 weeks after CH assessment. A total of 39 510 patients were evaluated in all subsequent analysis. (B) Prevalence of frequently mutated genes in CH based on age decile. (C) Distribution of mosaic chromosome alterations (MCAs) out of 35 134 evaluated patients using FACETS-CH. Alterations of chromosomes 5, 7, and 17 are highlighted in red because of their frequent association with high-risk therapy-related myeloid neoplasms. (D) The percentage of patients with CH stratified by primary solid cancer diagnosis per age decile. (E) Percentage of patients with CH among patients exposed to drugs with specified anticancer mechanisms before assessment. Many patients were exposed to &gt;1 drug mechanism. Data are from institutional pharmacy administration records which do not include anticancer therapies prescribed by non-MSK oncologists. (F) Density plots showing distribution of basic hematologic indices. Hemoglobin is reported in grams per deciliter. WBCs (white blood cells) and platelets are reported as 10<sup>9</sup> cells per liter. Vertical lines represent the median of each distribution. (G-H) Cumulative incidence of (G) hematologic malignancy and (H) death in patients with and without CH. HRs and <italic toggle="yes">P</italic> values were calculated using a multivariate competing risk regression, adjusting for age, gender, and cancer type.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-011262-gr1.jpg"/></fig></p>
          <p id="p0070">The fraction of patients with CH correlated strongly with age with little variation by cancer diagnosis (<xref rid="fig1" ref-type="fig">Figure 1</xref>D; <xref rid="appsec1" ref-type="sec">supplemental Table 2</xref>). A total of 15 370 patients (38.9%) had received at least 1 anticancer therapeutic agent at MSK Cancer Center at the time of CH assessment. CH incidence was similar across patients exposed to different drug mechanisms (<xref rid="fig1" ref-type="fig">Figure 1</xref>E; <xref rid="appsec1" ref-type="sec">supplemental Figure 3</xref>). Complete blood counts within 14 days of sequencing were available for most patients (33 114) (<xref rid="fig1" ref-type="fig">Figure 1</xref>F; <xref rid="appsec1" ref-type="sec">supplemental Figure 4</xref>; <xref rid="appsec1" ref-type="sec">supplemental Table 2</xref>). Of these, 7114 patients (21.4%) were anemic (hemoglobin level &lt; 11 g/dL), 2956 (8.9%) were thrombocytopenic (platelet count &lt;150×10<sup>9</sup>/L), and 2847 (8.6%) were leukopenic (total white blood cell count &lt; 4). The distribution of hematologic parameters was similar in patients with and without CH.</p>
          <p id="p0075">We identified 216 hematologic malignancy diagnoses in the cohort made ≥15 days after blood samples were collected for CH evaluation. High mortality within the cohort limited total follow-up time. Of the 39 510 patients in the cohort, only 8413 were observed beyond 3 years, and only 1831 were observed beyond 5 years. Nonetheless, CH was strongly associated with increased risk of hematologic malignancy (HR = 1.93; 95% confidence interval [CI], 1.45-2.57; <italic toggle="yes">P</italic> &lt; .001; <xref rid="fig1" ref-type="fig">Figure 1</xref>G) and of death (HR, 1.11; 95% CI, 1.07-1.15; <italic toggle="yes">P</italic> ≤ .001; <xref rid="fig1" ref-type="fig">Figure 1</xref>H) in multivariate regressions modeling competing risk of the other outcome and adjusting for age, cancer diagnosis, and gender.</p>
        </sec>
        <sec id="sec3.2">
          <title>Identification of CH genotypes associated with high risk of hematologic malignancy</title>
          <p id="p0080">To identify the CH genotypes associated with highest risk of progression we considered CH variants implicated in prior studies (CH-PD<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> and M-CHIP/L-CHIP<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref>) and/or observed in at least 40 patients in this cohort (<xref rid="fig2" ref-type="fig">Figure 2</xref>A). We built cause-specific Cox proportional hazards models with Firth penalization and adjustment for age, cancer type, and gender for all 166 candidate genes. Nine genotypes were associated with a significantly increased rate of hematologic malignancy using a false discovery rate threshold of 0.1 (<xref rid="fig2" ref-type="fig">Figure 2</xref>B). Among these genes <italic toggle="yes">JAK2</italic>, <italic toggle="yes">RUNX1</italic>, and <italic toggle="yes">ASXL1</italic> primarily preceded myeloid malignancies (20 out of 26 total cases), <italic toggle="yes">XPO1</italic> and <italic toggle="yes">KMT2D</italic> exclusively preceded lymphoid malignancies (7 out of 7 total cases), and <italic toggle="yes">TP53</italic> and <italic toggle="yes">TET2</italic> preceded disease from both lineages relatively equally (17 total myeloid and 25 total lymphoid cases), consistent with what is known about the pathobiology associated with these variants.<xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref> Mutations in <italic toggle="yes">SUZ12</italic> and <italic toggle="yes">ERBB4</italic> are less well described in the context of CH and warrant further study. Notably, <italic toggle="yes">DNMT3A</italic> and <italic toggle="yes">PPM1D</italic> were not associated with increased rate of hematologic malignancy despite being highly prevalent.<fig id="fig2" position="float" orientation="portrait"><label>Figure 2.</label><caption><p><bold>Identification of CH genes associated with high risk of hematologic malignancy.</bold> (A) We evaluated 166 genes representing the union of 99 genes previously implicated in hematologic malignancy (CH-PD, M-CHIP, and L-CHIP)<sup>10,28</sup> and 131 genes mutated at least 40 times in our dataset (observed in ≥∼1 per 1000 individuals). We built cause-specific Cox hazard models with Firth penalized likelihood including adjustments for gender, age, and solid cancer type for all genes and identified 9 with significantly increased hazard rate of hematologic malignancy based on false discovery rate (FDR) &lt; 0.1. (B) HR and 95% CI for high risk CH genes (red, top) and selected comparators that did not meet high risk criteria (blue, bottom). (C) MCAs were divided into an alarm group involving 5/7/17 and an “other” group that did not involve these chromosomes. HRs for MCAs were calculated using the same models described earlier.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-011262-gr2.jpg"/></fig></p>
          <p id="p0085">We, next, evaluated mosaic chromosome alterations using the same risk model to define their association with hematologic malignancy in this cohort (<xref rid="fig2" ref-type="fig">Figure 2</xref>C). We considered alterations of chromosomes 5, 7, and 17 (5/7/17) as a separate group because they are associated with poor prognoses in myeloid neoplasms and are recurrent events in therapy-related myeloid leukemia. Alterations in 5/7/17 were strongly associated with subsequent hematologic malignancies.</p>
          <p id="p0090">These findings nominate specific genomic features placing patients at particularly high risk of hematologic malignancy. Special attention should be paid to those with mutations in <italic toggle="yes">JAK2</italic>, <italic toggle="yes">RUNX1</italic>, and <italic toggle="yes">XPO1</italic>. Specific comutation combinations may also place patients at high risk of hematologic malignancy (<xref rid="appsec1" ref-type="sec">supplemental Table 3</xref>), but larger data sets will be needed for statistical analyses of these sets. Mosaic chromosome alterations involving 5/7/17 are also associated with a high risk of hematologic malignancy and deserve attention similar to high-risk gene mutations.</p>
        </sec>
        <sec id="sec3.3">
          <title>Characteristics of hematologic malignancies predicted by CH</title>
          <p id="p0095">We, then, evaluated the ability of CH to detect hematologic malignancy disease subsets (<xref rid="fig3" ref-type="fig">Figure 3</xref>A). All 11 patients who developed an myeloproliferative neoplasm [MPN] (including myelodysplastic syndrome [MDS]/MPN overlap syndromes) had CH, including 9 of 11 with <italic toggle="yes">JAK2</italic> V617F mutations. In contrast, most patients who went on to develop therapy-related myeloid neoplasms (high-risk MDS or acute myeloid leukemia [AML]) as well most of those who went on to develop high-grade B-cell lymphomas did not have CH at the time of assessment. Only 1 of 8 AML cases with an AML-defining chromosomal translocation had CH at assessment, suggesting translocation-driven, therapy-related leukemia may be unrelated to CH. CH was identified in approximately half of the number of patients who went on to develop either myeloid malignancies (36 of 70 patients) or lymphoid malignancies (70 of 133 patients; <xref rid="appsec1" ref-type="sec">supplemental Figure 5</xref>). Although the HR for myeloid malignancy posed by CH (HR, 2.99; 95% CI, 1.82-4.91) trended higher than that for lymphoid malignancies (HR = 1.66; 95% CI, 1.17-2.36), the absolute risk of the myeloid malignancy trended lower.<fig id="fig3" position="float" orientation="portrait"><label>Figure 3.</label><caption><p><bold>The association of CH with hematologic malignancy varies according to the disease subtype.</bold> (A) Fraction of patients with CH among those who developed each of the hematologic malignancy types listed. We combined MDS and AML into a single therapy-related myeloid neoplasm (t-MN) group because therapy-related MDS behaves aggressively, and molecular characteristics better reflect pathogenesis and prognosis. Lymphoid malignancies are blue and myeloid are red. Total number of cases is presented at the top of each bar. (B) Fraction of patients who had preceding CH among those who developed chronic or acute hematologic malignancies. (C) Cumulative incidence of acute and chronic hematologic malignancies stratified based on the presence or absence of CH. All HRs and <italic toggle="yes">P</italic> values were calculated using a multivariate competing risk regression, adjusting for age, gender, and cancer type. CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MPN, myeloproliferative neoplasm; NOS, not otherwise specified. TP53/CK: TP53 mutation and/or complex karyotype.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-011262-gr3.jpg"/></fig></p>
          <p id="p0100">To put these findings into context we considered that cancer screening tests contend with length bias which causes a skew in diagnosis toward disease that progresses more slowly.<xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref> Similarly, the ability to use CH to detect a preclinical phase of hematologic disease is related to the length of time the disease is both detectable and preclinical. To evaluate chronicity in the context of CH, we divided hematologic malignancies into chronic diseases, including MPN, chronic myeloid leukemia, chronic lymphocytic leukemia, and low-grade B-cell lymphoma, and acute diseases, including MDS or AML presenting as a therapy-related myeloid neoplasm and high-grade B-cell lymphoma. CH occurred before 81 of 136 (59.6%) of chronic hematologic malignancies and 26 of 66 (39.4%) of acute malignancies (<xref rid="fig3" ref-type="fig">Figure 3</xref>B). Patients with CH had a significantly increased risk of chronic hematologic malignancies (HR = 3.3; 95% CI, 2.36-4.6; <italic toggle="yes">P</italic> &lt; .001) but not acute hematologic malignancies (HR = 1.49; 95% CI, 0.93-2.39; <italic toggle="yes">P</italic> = .10; <xref rid="fig3" ref-type="fig">Figure 3</xref>C). These results suggest that length bias should be considered when the predictive use of CH is evaluated.</p>
        </sec>
        <sec id="sec3.4">
          <title>Relationship between clonal selection and risk of hematologic malignancy</title>
          <p id="p0105">Somatic mutation acquisition in human tissues can be modeled as an evolutionary process driven by acquisition of mutations under positive selection.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Using this perspective, the enrichment of dN/dS is a common manner in which driver mutations are defined.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> To understand selective forces in our cohort, we calculated genomic context-corrected dN/dS (dNdScv) and plotted HR for hematologic malignancy as a function of dNdScv (<xref rid="fig4" ref-type="fig">Figure 4</xref>). We observed a weak inverse correlation between the 2 parameters (Kendall τ = −0.09). Interestingly, variants with the strongest evidence for positive selection were primarily those with the highest prevalence of mutations across CH studies (<italic toggle="yes">DNMT3A</italic>, <italic toggle="yes">TET2</italic>, and <italic toggle="yes">ASXL1</italic>) and those involved in the DNA damage response (<italic toggle="yes">TP53</italic> and <italic toggle="yes">CHEK2</italic>). Although mutations in some of these genes are associated with an increased risk of hematologic malignancy, this risk was lower than that imposed by mutations in <italic toggle="yes">RUNX1</italic> and <italic toggle="yes">XPO1</italic>, which had much lower dNdScv valuations. These results argue that risk of hematologic malignancy is not reducible to the factors that make CH clones increase in size.<fig id="fig4" position="float" orientation="portrait"><label>Figure 4.</label><caption><p><bold>Relationship between nonsynonymous mutation enrichment and risk of hematologic malignancy.</bold> Gene-specific HRs for hematologic neoplasm (as calculated in <xref rid="fig2" ref-type="fig">Figure 2</xref>) are plotted as a function of context-corrected nonsynonymous mutation enrichment (dNdScv). High-risk CH genotypes identified in <xref rid="fig2" ref-type="fig">Figure 2</xref> are labeled in red, whereas other selected genotypes are labeled in blue. Kendall τ statistic was used to quantify the relationship (centered, top). A linear trend line is displayed for visual reference.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-011262-gr4.jpg"/></fig></p>
        </sec>
        <sec id="sec3.5">
          <title>Association of silent CH with hematologic malignancy</title>
          <p id="p0110">We, next, expanded our analyses to include all variants with the potential to provide information about clonal architecture. To this end we identified a set of “silent CH” variants combining synonymous mutations in protein-coding regions and nonsplice site mutations in noncoding regions (<xref rid="fig5" ref-type="fig">Figure 5</xref>A). The largest categories of silent CH variants in our data set were synonymous variants in coding regions (2247; 28.7%) and variants in introns (5021; 64.2%; <xref rid="fig5" ref-type="fig">Figure 5</xref>B). Silent CH was enriched in older patients, similar to conventional CH (<xref rid="fig5" ref-type="fig">Figure 5</xref>C). Additionally, the 2 groups had similar distributions of variant allele fractions (<xref rid="fig5" ref-type="fig">Figure 5</xref>D). Both conventional and silent CH were dominated by single nucleotide transversions with a similar distribution of nucleotide changes, with the major difference being that complex DNA changes were less common in silent CH (<xref rid="fig5" ref-type="fig">Figure 5</xref>E; Pearson r = 0.95 correlating number of mutations observed in 7 categories including the 6 types of single nucleotide changes and complex changes). Although any DNA mutation has potential to alter cellular fitness, we observed few recurrent silent CH mutations compared with conventional CH mutations (<xref rid="fig5" ref-type="fig">Figure 5</xref>F), arguing against widespread selective influence. Silent CH may, therefore, have the potential to reveal the impact of restricted clonal architecture separate from CH mutation function.<fig id="fig5" position="float" orientation="portrait"><label>Figure 5.</label><caption><p><bold>Silent CH and its associated hazards.</bold> (A) Comparison of number of patients with silent CH vs conventional CH. (B) Variant classes contributing to silent CH. (C) Age distribution of conventional and silent CH mutations. (D) Comparison of the VAF distributions of silent and conventional CH variants. (E) Number of specific single DNA base alterations in conventional and silent CH, and number of more complex alterations in each group. (F) Histogram showing number of observations of specific DNA variants in conventional and silent CH groups. (G) HR for hematologic malignancy in patients with conventional vs silent CH. Silent CH has minimal significance as an isolated finding at low VAF in a single gene but attains significance and expands the number of higher risk patients identifiable when it is present in combination with other mutations and/or when VAF is &gt;0.1. HRs and <italic toggle="yes">P</italic> values were calculated using a multivariate competing risk regression, adjusting for age, gender, and cancer type.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-011262-gr5.jpg"/></fig></p>
          <p id="p0115">We measured the HR for hematologic malignancy in patients with silent CH (<xref rid="fig5" ref-type="fig">Figure 5</xref>G). When patients with isolated silent CH (who did not also have conventional CH) were considered in aggregate, risk of hematologic malignancy was not significantly increased. When patients with conventional and silent CH were identified nonexclusively, the risk of hematologic malignancy stratified either by VAF or mutation number was similar in each group. The number of patients at risk of hematologic malignancy because of the presence of multiple CH mutations increased significantly from 3871 to 6111 when silent CH mutations were considered along with conventional CH mutations, with minimal change in the HR (HR, 2.54; 95% CI, 1.78-3.62 in the former group and HR, 2.45; 95% CI, 1.75-3.44 in the latter group). Additionally, consideration of the union of patients with either CH type with at least 1 high VAF mutation expanded the pool of patients at elevated risk (3070 patients with a conventional CH VAF &gt; 10% had HR, 2.93 [95% CI, 2.01-4.25], whereas the liberalized set of 4204 patients with either conventional or silent VAF &gt; 10% had HR, 2.83 [95% CI, 1.97-4.06]). To confirm that the risks associated with silent CH are unlikely to be due to unannotated functional variants, we performed sensitivity analyses examining synonymous coding region variants and other variants separately. In age-adjusted models comparing the binary presence or absence of all silent CH, synonymous coding silent CH, and other silent CH HRs were similar (all silent CH: HR, 1.67; 95% CI, 1.23-2.27; synonymous coding HR, 1.70; 95% CI, 1.10-2.65; other silent variant HR, 1.48; 95% CI, 1.03-.211). In contrast to conventional CH, silent CH was not strongly associated with mortality in our cohort (<xref rid="appsec1" ref-type="sec">supplemental Figure 6</xref>). Altogether, these findings show that that single silent nonprotein coding changes identified in gene panel sequencing have predictive significance.</p>
        </sec>
        <sec id="sec3.6">
          <title>Detection of CH mutations in subsequent hematologic malignancies</title>
          <p id="p0120">CH variants predating the diagnosis of a hematologic malignancy could be present in clones that are disease precursors or disease bystanders. In the former case, the observed VAF is likely to increase at the manifestation of clinical disease. We looked for evidence of clonal expansion in hematologic malignancy cases sequenced with MSK IMPACT that arose in patients in which at least 1 CH variant was identified. 84 variants in 26 cases were identified. Variants in 6 genes (<italic toggle="yes">ASXL1</italic>, <italic toggle="yes">CHEK2</italic>, <italic toggle="yes">DNMT3A</italic>, <italic toggle="yes">JAK2</italic>, <italic toggle="yes">TET2</italic>, and <italic toggle="yes">TP53</italic>) were observed at least three times. We visualized the clonal trajectory of each recurrent variant from CH assessment to disease (<xref rid="fig6" ref-type="fig">Figure 6</xref>). All six <italic toggle="yes">JAK2</italic> variants and all four <italic toggle="yes">TP53</italic> variants increased in size consistent with a disease-deterministic role of these variants. In contrast, only 2 of 7 <italic toggle="yes">DNMT3A</italic> variants had a higher VAF at disease diagnosis than at CH assessment arguing against a universal constitutional role in disease.<fig id="fig6" position="float" orientation="portrait"><label>Figure 6.</label><caption><p><bold>Clonal trajectories of CH mutations during the evolution of 26 subsequent hematologic malignancies.</bold> Six CH genes were present in at least 3 patients who subsequently developed a hematologic malignancy that was also sequenced using the MSK IMPACT platform. Vector origins at time zero show CH VAF in blood, and vector termini show VAF in the bone marrow at time of hematologic disease characterization.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-011262-gr6.jpg"/></fig></p>
          <p id="p0125">We next divided the full variant set based on disease category and conventional vs silent CH type (<xref rid="appsec1" ref-type="sec">supplemental Figure 7</xref>). Of the half of all CH variants with VAF &gt; 0.1, 27 of these 42 (64.3%) were larger at time of disease assessment, whereas only 14 of 42 (33.3%) expanded when CH VAF was less than 0.1. Additionally, a greater fraction of conventional CH mutations (33 of 60; 55%) expanded than silent CH mutations (8 of 24; 33%). However, silent variants with VAF &gt; 0.1 expanded in 7 of 12 cases (58.3%), suggesting that large VAF may be the best predictor of future growth in many situations. Altogether these data suggest that the participation of specific CH genotypes in subsequent disease processes is variable. Higher risk CH mutations may be more likely to be true disease precursors, whereas lower-risk mutations more likely to be disease bystanders.</p>
        </sec>
      </sec>
      <sec id="sec4">
        <title>Discussion</title>
        <p id="p0130">We analyzed cancer-related gene sequences in the blood of patients with solid tumors to better understand the relationship between clonal hematopoiesis and hematologic malignancy in this population. We found that mutations in <italic toggle="yes">JAK2</italic> were strongly associated with subsequent MPN, <italic toggle="yes">RUNX1</italic> mutations with subsequent therapy-related myeloid neoplasms (MDS/AML), and <italic toggle="yes">XPO1</italic> mutations with subsequent chronic lymphocytic leukemia. Despite disparate patient populations and detection methods, our findings are consistent with a recent study in healthy subjects similarly focusing attention on a smaller number of high-risk CH mutations.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref></p>
        <p id="p0135">Importantly, we failed to observe strong associations between several canonical myeloid driver genes and hematologic malignancy. <italic toggle="yes">DNMT3A</italic> mutations were poor predictors of hematologic malignancy despite substantial statistical power. In contrast, failure to implicate <italic toggle="yes">FLT3</italic> and <italic toggle="yes">NPM1</italic> as being associated with a high risk of myeloid leukemia was likely because they are associated with rapid onset of disease making the time window during which they are detectable as CH short. Although rare, CH characterized by pathogenic mutations in these genes deserves close attention.</p>
        <p id="p0140">In our cohort, silent CH variants were associated with a modest but significant risk of hematologic malignancy. Most of these mutations are not expected to affect cellular fitness; thus, silent CH is likely a marker of something else that increases the risk of hematologic malignancy. Either of 2 likely scenarios could be responsible: (1) the neutral mutations are passengers associated with hematopoietic clones with a causal role in disease or (2) the detection of any CH indicates a state of low clonal diversity predisposed to foster other malignant clones.</p>
        <p id="p0145">Our study has important limitations. First, it was carried out exclusively in patients with nonhematologic cancer. Most patients received anticancer therapy, and many received traditional cytotoxic chemotherapy. The significance of our findings in people who do not have cancer is uncertain. Second, the median follow-up duration was limited, in large part because of nonhematologic cancer–related mortality. Therapy-related hematologic malignancies that progress over longer time scales were probably not well captured. We anticipate that as additional large-scale studies expand the genomic and clinical data available that we will learn that many factors contribute to clonal evolution and disease progression in addition to mutations in known CH-driver genes.</p>
      </sec>
      <sec sec-type="COI-statement">
        <p id="p0150">Conflict-of-interest disclosure: A.J.S. (spouse is an employee of Bristol Myers Squibb). R.N.P. is an employee of C2i Genomics. S.F.E. is an employee of Tempus Labs. W.X. has received research support from <funding-source id="gs5">Stemline Therapeutics</funding-source>. M.F.B. has received consulting fees from Eli Lilly and AstraZeneca. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Bakx, Zentalis, Ajax, Auron, Prelude, C4 Therapeutics, and Isoplexis; has received research support from <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006483</institution-id><institution>AbbVie</institution></institution-wrap></funding-source>, <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100025208</institution-id><institution>Constellation</institution></institution-wrap></funding-source>, <funding-source id="gs8">Ajax</funding-source>, <funding-source id="gs9">Zentalis</funding-source>, and <funding-source id="gs10">Prelude</funding-source>; has received research support from and consulted for <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006436</institution-id><institution>Celgene</institution></institution-wrap></funding-source> and <funding-source id="gs12"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>; and has consulted for Syndax, Incyte, Janssen, Astellas, MorphoSys, and Novartis, and received honoraria from AstraZeneca, Novartis, Gilead and Novartis. S.M. has financial interests in a patent application relating to software described in this article (CEDARS: Clinical Event Detection and Recording System) and is principal owner of Daboia Consulting LLC. The remaining authors declare no competing financial interests.</p>
        <p id="p0155">The current affiliation for S.F.-E. is Tempus Labs, New York, NY.</p>
        <p id="p0160">The current affiliation for R.N.P is C2i genomics, New York, NY.</p>
        <p id="p0165">The current affiliation for B.S. is Hackensack University Medical Center, Hackensack, NJ.</p>
      </sec>
    </body>
    <back>
      <ref-list id="cebib0010">
        <title>References</title>
        <ref id="bib1">
          <label>1</label>
          <element-citation publication-type="journal" id="sref1">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Aksoy</surname>
                <given-names>BA</given-names>
              </name>
              <name name-style="western">
                <surname>Dogrusoz</surname>
                <given-names>U</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>
            <source>Sci Signal</source>
            <volume>6</volume>
            <issue>269</issue>
            <year>2013</year>
            <fpage>pl1</fpage>
            <pub-id pub-id-type="pmid">23550210</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.2004088</pub-id>
            <pub-id pub-id-type="pmcid">PMC4160307</pub-id>
          </element-citation>
        </ref>
        <ref id="bib2">
          <label>2</label>
          <element-citation publication-type="journal" id="sref2">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bolton</surname>
                <given-names>KL</given-names>
              </name>
              <name name-style="western">
                <surname>Ptashkin</surname>
                <given-names>RN</given-names>
              </name>
              <name name-style="western">
                <surname>Gao</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Cancer therapy shapes the fitness landscape of clonal hematopoiesis</article-title>
            <source>Nat Genet</source>
            <volume>52</volume>
            <issue>11</issue>
            <year>2020</year>
            <fpage>1219</fpage>
            <lpage>1226</lpage>
            <pub-id pub-id-type="pmid">33106634</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-020-00710-0</pub-id>
            <pub-id pub-id-type="pmcid">PMC7891089</pub-id>
          </element-citation>
        </ref>
        <ref id="bib3">
          <label>3</label>
          <element-citation publication-type="journal" id="sref3">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jaiswal</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Ebert</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Clonal hematopoiesis in human aging and disease</article-title>
            <source>Science</source>
            <volume>366</volume>
            <issue>6465</issue>
            <year>2019</year>
            <object-id pub-id-type="publisher-id">eaan4673</object-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan4673</pub-id>
            <pub-id pub-id-type="pmcid">PMC8050831</pub-id>
            <pub-id pub-id-type="pmid">31672865</pub-id>
          </element-citation>
        </ref>
        <ref id="bib4">
          <label>4</label>
          <element-citation publication-type="journal" id="sref4">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kaner</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Desai</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Mencia-Trinchant</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Guzman</surname>
                <given-names>ML</given-names>
              </name>
              <name name-style="western">
                <surname>Roboz</surname>
                <given-names>GJ</given-names>
              </name>
              <name name-style="western">
                <surname>Hassane</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Clonal hematopoiesis and premalignant diseases</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <volume>10</volume>
            <issue>4</issue>
            <year>2020</year>
            <fpage>a035675</fpage>
            <pub-id pub-id-type="pmid">31615870</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a035675</pub-id>
            <pub-id pub-id-type="pmcid">PMC7117948</pub-id>
          </element-citation>
        </ref>
        <ref id="bib5">
          <label>5</label>
          <element-citation publication-type="journal" id="sref5">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Warren</surname>
                <given-names>JT</given-names>
              </name>
              <name name-style="western">
                <surname>Link</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Clonal hematopoiesis and risk for hematologic malignancy</article-title>
            <source>Blood</source>
            <volume>136</volume>
            <issue>14</issue>
            <year>2020</year>
            <fpage>1599</fpage>
            <lpage>1605</lpage>
            <pub-id pub-id-type="pmid">32736382</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2019000991</pub-id>
            <pub-id pub-id-type="pmcid">PMC8209630</pub-id>
          </element-citation>
        </ref>
        <ref id="bib6">
          <label>6</label>
          <element-citation publication-type="journal" id="sref6">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Genovese</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Kähler</surname>
                <given-names>AK</given-names>
              </name>
              <name name-style="western">
                <surname>Handsaker</surname>
                <given-names>RE</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence</article-title>
            <source>N Engl J Med</source>
            <volume>371</volume>
            <issue>26</issue>
            <year>2014</year>
            <fpage>2477</fpage>
            <lpage>2487</lpage>
            <pub-id pub-id-type="pmid">25426838</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1409405</pub-id>
            <pub-id pub-id-type="pmcid">PMC4290021</pub-id>
          </element-citation>
        </ref>
        <ref id="bib7">
          <label>7</label>
          <element-citation publication-type="journal" id="sref7">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jaiswal</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Fontanillas</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Flannick</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Age-related clonal hematopoiesis associated with adverse outcomes</article-title>
            <source>N Engl J Med</source>
            <volume>371</volume>
            <issue>26</issue>
            <year>2014</year>
            <fpage>2488</fpage>
            <lpage>2498</lpage>
            <pub-id pub-id-type="pmid">25426837</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1408617</pub-id>
            <pub-id pub-id-type="pmcid">PMC4306669</pub-id>
          </element-citation>
        </ref>
        <ref id="bib8">
          <label>8</label>
          <element-citation publication-type="journal" id="sref8">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zink</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Stacey</surname>
                <given-names>SN</given-names>
              </name>
              <name name-style="western">
                <surname>Norddahl</surname>
                <given-names>GL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly</article-title>
            <source>Blood</source>
            <volume>130</volume>
            <issue>6</issue>
            <year>2017</year>
            <fpage>742</fpage>
            <lpage>752</lpage>
            <pub-id pub-id-type="pmid">28483762</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2017-02-769869</pub-id>
            <pub-id pub-id-type="pmcid">PMC5553576</pub-id>
          </element-citation>
        </ref>
        <ref id="bib9">
          <label>9</label>
          <element-citation publication-type="journal" id="sref9">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Abelson</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Collord</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Ng</surname>
                <given-names>SWK</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Prediction of acute myeloid leukaemia risk in healthy individuals</article-title>
            <source>Nature</source>
            <volume>559</volume>
            <issue>7714</issue>
            <year>2018</year>
            <fpage>400</fpage>
            <lpage>404</lpage>
            <pub-id pub-id-type="pmid">29988082</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0317-6</pub-id>
            <pub-id pub-id-type="pmcid">PMC6485381</pub-id>
          </element-citation>
        </ref>
        <ref id="bib10">
          <label>10</label>
          <element-citation publication-type="journal" id="sref10">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Coombs</surname>
                <given-names>CC</given-names>
              </name>
              <name name-style="western">
                <surname>Zehir</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Devlin</surname>
                <given-names>SM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes</article-title>
            <source>Cell Stem Cell</source>
            <volume>21</volume>
            <issue>3</issue>
            <year>2017</year>
            <fpage>374</fpage>
            <lpage>382.e4</lpage>
            <pub-id pub-id-type="pmid">28803919</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.stem.2017.07.010</pub-id>
            <pub-id pub-id-type="pmcid">PMC5591073</pub-id>
          </element-citation>
        </ref>
        <ref id="bib11">
          <label>11</label>
          <element-citation publication-type="journal" id="sref11">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Desai</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Mencia-Trinchant</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Savenkov</surname>
                <given-names>O</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Somatic mutations precede acute myeloid leukemia years before diagnosis</article-title>
            <source>Nat Med</source>
            <volume>24</volume>
            <issue>7</issue>
            <year>2018</year>
            <fpage>1015</fpage>
            <lpage>1023</lpage>
            <pub-id pub-id-type="pmid">29988143</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0081-z</pub-id>
            <pub-id pub-id-type="pmcid">PMC6849383</pub-id>
          </element-citation>
        </ref>
        <ref id="bib12">
          <label>12</label>
          <element-citation publication-type="journal" id="sref12">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Kantarjian</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study</article-title>
            <source>Lancet Oncol</source>
            <volume>18</volume>
            <issue>1</issue>
            <year>2017</year>
            <fpage>100</fpage>
            <lpage>111</lpage>
            <pub-id pub-id-type="pmid">27923552</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(16)30626-X</pub-id>
            <pub-id pub-id-type="pmcid">PMC5405697</pub-id>
          </element-citation>
        </ref>
        <ref id="bib13">
          <label>13</label>
          <element-citation publication-type="journal" id="sref13">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fujino</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Kitamura</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>ASXL1 mutation in clonal hematopoiesis</article-title>
            <source>Exp Hematol</source>
            <volume>83</volume>
            <year>2020</year>
            <fpage>74</fpage>
            <lpage>84</lpage>
            <pub-id pub-id-type="pmid">31945396</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exphem.2020.01.002</pub-id>
          </element-citation>
        </ref>
        <ref id="bib14">
          <label>14</label>
          <element-citation publication-type="journal" id="sref14">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mayle</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Rodriguez</surname>
                <given-names>B</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation</article-title>
            <source>Blood</source>
            <volume>125</volume>
            <issue>4</issue>
            <year>2015</year>
            <fpage>629</fpage>
            <lpage>638</lpage>
            <pub-id pub-id-type="pmid">25416277</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2014-08-594648</pub-id>
            <pub-id pub-id-type="pmcid">PMC4304108</pub-id>
          </element-citation>
        </ref>
        <ref id="bib15">
          <label>15</label>
          <element-citation publication-type="journal" id="sref15">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shih</surname>
                <given-names>AH</given-names>
              </name>
              <name name-style="western">
                <surname>Abdel-Wahab</surname>
                <given-names>O</given-names>
              </name>
              <name name-style="western">
                <surname>Patel</surname>
                <given-names>JP</given-names>
              </name>
              <name name-style="western">
                <surname>Levine</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>The role of mutations in epigenetic regulators in myeloid malignancies</article-title>
            <source>Nat Rev Cancer</source>
            <volume>12</volume>
            <issue>9</issue>
            <year>2012</year>
            <fpage>599</fpage>
            <lpage>612</lpage>
            <pub-id pub-id-type="pmid">22898539</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3343</pub-id>
          </element-citation>
        </ref>
        <ref id="bib16">
          <label>16</label>
          <element-citation publication-type="journal" id="sref16">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Martincorena</surname>
                <given-names>I</given-names>
              </name>
              <name name-style="western">
                <surname>Raine</surname>
                <given-names>KM</given-names>
              </name>
              <name name-style="western">
                <surname>Gerstung</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Universal patterns of selection in cancer and somatic tissues</article-title>
            <source>Cell</source>
            <volume>171</volume>
            <issue>5</issue>
            <year>2017</year>
            <fpage>1029</fpage>
            <lpage>1041.e21</lpage>
            <pub-id pub-id-type="pmid">29056346</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.09.042</pub-id>
            <pub-id pub-id-type="pmcid">PMC5720395</pub-id>
          </element-citation>
        </ref>
        <ref id="bib17">
          <label>17</label>
          <element-citation publication-type="journal" id="sref17">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Weeks</surname>
                <given-names>LD</given-names>
              </name>
              <name name-style="western">
                <surname>Niroula</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Neuberg</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Prediction of risk for myeloid malignancy in clonal hematopoiesis</article-title>
            <source>NEJM Evid</source>
            <volume>2</volume>
            <issue>5</issue>
            <year>2023</year>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/evidoa2200310</pub-id>
            <pub-id pub-id-type="pmcid">PMC10361696</pub-id>
            <pub-id pub-id-type="pmid">37483562</pub-id>
          </element-citation>
        </ref>
        <ref id="bib18">
          <label>18</label>
          <element-citation publication-type="journal" id="sref18">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gu</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Kovilakam</surname>
                <given-names>SC</given-names>
              </name>
              <name name-style="western">
                <surname>Dunn</surname>
                <given-names>WG</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Multiparameter prediction of myeloid neoplasia risk</article-title>
            <source>Nat Genet</source>
            <volume>55</volume>
            <issue>9</issue>
            <year>2023</year>
            <fpage>1523</fpage>
            <lpage>1530</lpage>
            <pub-id pub-id-type="pmid">37620601</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-023-01472-1</pub-id>
            <pub-id pub-id-type="pmcid">PMC10484784</pub-id>
          </element-citation>
        </ref>
        <ref id="bib19">
          <label>19</label>
          <element-citation publication-type="journal" id="sref19">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Watson</surname>
                <given-names>CJ</given-names>
              </name>
              <name name-style="western">
                <surname>Papula</surname>
                <given-names>AL</given-names>
              </name>
              <name name-style="western">
                <surname>Poon</surname>
                <given-names>GYP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The evolutionary dynamics and fitness landscape of clonal hematopoiesis</article-title>
            <source>Science</source>
            <volume>367</volume>
            <issue>6485</issue>
            <year>2020</year>
            <fpage>1449</fpage>
            <lpage>1454</lpage>
            <pub-id pub-id-type="pmid">32217721</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aay9333</pub-id>
          </element-citation>
        </ref>
        <ref id="bib20">
          <label>20</label>
          <element-citation publication-type="journal" id="sref20">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fabre</surname>
                <given-names>MA</given-names>
              </name>
              <name name-style="western">
                <surname>de Almeida</surname>
                <given-names>JG</given-names>
              </name>
              <name name-style="western">
                <surname>Fiorillo</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The longitudinal dynamics and natural history of clonal haematopoiesis</article-title>
            <source>Nature</source>
            <volume>606</volume>
            <issue>7913</issue>
            <year>2022</year>
            <fpage>335</fpage>
            <lpage>342</lpage>
            <pub-id pub-id-type="pmid">35650444</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04785-z</pub-id>
            <pub-id pub-id-type="pmcid">PMC9177423</pub-id>
          </element-citation>
        </ref>
        <ref id="bib21">
          <label>21</label>
          <element-citation publication-type="journal" id="sref21">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mitchell</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Spencer Chapman</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Williams</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clonal dynamics of haematopoiesis across the human lifespan</article-title>
            <source>Nature</source>
            <volume>606</volume>
            <issue>7913</issue>
            <year>2022</year>
            <fpage>343</fpage>
            <lpage>350</lpage>
            <pub-id pub-id-type="pmid">35650442</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04786-y</pub-id>
            <pub-id pub-id-type="pmcid">PMC9177428</pub-id>
          </element-citation>
        </ref>
        <ref id="bib22">
          <label>22</label>
          <element-citation publication-type="journal" id="sref22">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Churpek</surname>
                <given-names>JE</given-names>
              </name>
              <name name-style="western">
                <surname>Larson</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The evolving challenge of therapy-related myeloid neoplasms</article-title>
            <source>Best Pract Res Clin Haematol</source>
            <volume>26</volume>
            <issue>4</issue>
            <year>2013</year>
            <fpage>309</fpage>
            <lpage>317</lpage>
            <pub-id pub-id-type="pmid">24507808</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.beha.2013.09.001</pub-id>
            <pub-id pub-id-type="pmcid">PMC3920194</pub-id>
          </element-citation>
        </ref>
        <ref id="bib23">
          <label>23</label>
          <element-citation publication-type="journal" id="sref23">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>McNerney</surname>
                <given-names>ME</given-names>
              </name>
              <name name-style="western">
                <surname>Godley</surname>
                <given-names>LA</given-names>
              </name>
              <name name-style="western">
                <surname>Le Beau</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Therapy-related myeloid neoplasms: when genetics and environment collide</article-title>
            <source>Nat Rev Cancer</source>
            <volume>17</volume>
            <issue>9</issue>
            <year>2017</year>
            <fpage>513</fpage>
            <lpage>527</lpage>
            <pub-id pub-id-type="pmid">28835720</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc.2017.60</pub-id>
            <pub-id pub-id-type="pmcid">PMC5946699</pub-id>
          </element-citation>
        </ref>
        <ref id="bib24">
          <label>24</label>
          <element-citation publication-type="journal" id="sref24">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cheng</surname>
                <given-names>DT</given-names>
              </name>
              <name name-style="western">
                <surname>Mitchell</surname>
                <given-names>TN</given-names>
              </name>
              <name name-style="western">
                <surname>Zehir</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology</article-title>
            <source>J Mol Diagn</source>
            <volume>17</volume>
            <issue>3</issue>
            <year>2015</year>
            <fpage>251</fpage>
            <lpage>264</lpage>
            <pub-id pub-id-type="pmid">25801821</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmoldx.2014.12.006</pub-id>
            <pub-id pub-id-type="pmcid">PMC5808190</pub-id>
          </element-citation>
        </ref>
        <ref id="bib25">
          <label>25</label>
          <element-citation publication-type="journal" id="sref25">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shen</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Seshan</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing</article-title>
            <source>Nucleic Acids Res</source>
            <volume>44</volume>
            <issue>16</issue>
            <year>2016</year>
            <fpage>e131</fpage>
            <pub-id pub-id-type="pmid">27270079</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkw520</pub-id>
            <pub-id pub-id-type="pmcid">PMC5027494</pub-id>
          </element-citation>
        </ref>
        <ref id="bib26">
          <label>26</label>
          <element-citation publication-type="journal" id="sref26">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gao</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Ptashkin</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Bolton</surname>
                <given-names>KL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis</article-title>
            <source>Nat Commun</source>
            <volume>12</volume>
            <issue>1</issue>
            <year>2021</year>
            <fpage>338</fpage>
            <pub-id pub-id-type="pmid">33436578</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-20565-7</pub-id>
            <pub-id pub-id-type="pmcid">PMC7804935</pub-id>
          </element-citation>
        </ref>
        <ref id="bib27">
          <label>27</label>
          <element-citation publication-type="journal" id="sref27">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Franch-Expósito</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Mehine</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Ptashkin</surname>
                <given-names>RN</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Associations between cancer predisposition mutations and clonal hematopoiesis in patients with solid tumors</article-title>
            <source>JCO Precis Oncol</source>
            <volume>7</volume>
            <year>2023</year>
            <object-id pub-id-type="publisher-id">e2300070</object-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.23.00070</pub-id>
            <pub-id pub-id-type="pmcid">PMC10581611</pub-id>
            <pub-id pub-id-type="pmid">37561983</pub-id>
          </element-citation>
        </ref>
        <ref id="bib28">
          <label>28</label>
          <element-citation publication-type="journal" id="sref28">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Niroula</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Sekar</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Murakami</surname>
                <given-names>MA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Distinction of lymphoid and myeloid clonal hematopoiesis</article-title>
            <source>Nat Med</source>
            <volume>27</volume>
            <issue>11</issue>
            <year>2021</year>
            <fpage>1921</fpage>
            <lpage>1927</lpage>
            <pub-id pub-id-type="pmid">34663986</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01521-4</pub-id>
            <pub-id pub-id-type="pmcid">PMC8621497</pub-id>
          </element-citation>
        </ref>
        <ref id="bib29">
          <label>29</label>
          <element-citation publication-type="journal" id="sref29">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Novel mutations and their functional and clinical relevance in myeloproliferativeneoplasms: <italic toggle="yes">JAK2, MPL, TET2, ASXL1, CBL, IDH</italic> and <italic toggle="yes">IKZF1</italic></article-title>
            <source>Leukemia</source>
            <volume>24</volume>
            <issue>6</issue>
            <year>2010</year>
            <fpage>1128</fpage>
            <lpage>1138</lpage>
            <pub-id pub-id-type="pmid">20428194</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/leu.2010.69</pub-id>
            <pub-id pub-id-type="pmcid">PMC3035972</pub-id>
          </element-citation>
        </ref>
        <ref id="bib30">
          <label>30</label>
          <element-citation publication-type="journal" id="sref30">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Christiansen</surname>
                <given-names>DH</given-names>
              </name>
              <name name-style="western">
                <surname>Andersen</surname>
                <given-names>MK</given-names>
              </name>
              <name name-style="western">
                <surname>Pedersen-Bjergaard</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation</article-title>
            <source>Blood</source>
            <volume>104</volume>
            <issue>5</issue>
            <year>2004</year>
            <fpage>1474</fpage>
            <lpage>1481</lpage>
            <pub-id pub-id-type="pmid">15142876</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2004-02-0754</pub-id>
          </element-citation>
        </ref>
        <ref id="bib31">
          <label>31</label>
          <element-citation publication-type="journal" id="sref31">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Scott</surname>
                <given-names>LM</given-names>
              </name>
              <name name-style="western">
                <surname>Tong</surname>
                <given-names>W</given-names>
              </name>
              <name name-style="western">
                <surname>Levine</surname>
                <given-names>RL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis</article-title>
            <source>N Engl J Med</source>
            <volume>356</volume>
            <issue>5</issue>
            <year>2007</year>
            <fpage>459</fpage>
            <lpage>468</lpage>
            <pub-id pub-id-type="pmid">17267906</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa065202</pub-id>
            <pub-id pub-id-type="pmcid">PMC2873834</pub-id>
          </element-citation>
        </ref>
        <ref id="bib32">
          <label>32</label>
          <element-citation publication-type="journal" id="sref32">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tueur</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Lazarian</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Eclache</surname>
                <given-names>V</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort</article-title>
            <source>Br J Haematol</source>
            <volume>191</volume>
            <issue>3</issue>
            <year>2020</year>
            <fpage>e90</fpage>
            <lpage>e94</lpage>
            <pub-id pub-id-type="pmid">32790071</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjh.17046</pub-id>
          </element-citation>
        </ref>
        <ref id="bib33">
          <label>33</label>
          <element-citation publication-type="journal" id="sref33">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ortega-Molina</surname>
                <given-names>Ana</given-names>
              </name>
              <name name-style="western">
                <surname>Boss</surname>
                <given-names>IW</given-names>
              </name>
              <name name-style="western">
                <surname>Canela</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development</article-title>
            <source>Nat Med</source>
            <volume>21</volume>
            <issue>10</issue>
            <year>2015</year>
            <fpage>1199</fpage>
            <lpage>1208</lpage>
            <pub-id pub-id-type="pmid">26366710</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3943</pub-id>
            <pub-id pub-id-type="pmcid">PMC4676270</pub-id>
          </element-citation>
        </ref>
        <ref id="bib34">
          <label>34</label>
          <element-citation publication-type="journal" id="sref34">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cole</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Morrison</surname>
              </name>
            </person-group>
            <article-title>AS Basic issues in population screening for cancer</article-title>
            <source>J Natl Cancer Inst</source>
            <volume>64</volume>
            <issue>5</issue>
            <year>1980</year>
            <fpage>1263</fpage>
            <lpage>1272</lpage>
            <pub-id pub-id-type="pmid">6767876</pub-id>
          </element-citation>
        </ref>
        <ref id="bib35">
          <label>35</label>
          <element-citation publication-type="journal" id="sref35">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Grimes</surname>
                <given-names>DA</given-names>
              </name>
              <name name-style="western">
                <surname>Schulz</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>Uses and abuses of screening tests</article-title>
            <source>Lancet</source>
            <volume>359</volume>
            <issue>9309</issue>
            <year>2002</year>
            <fpage>881</fpage>
            <lpage>884</lpage>
            <pub-id pub-id-type="pmid">11897304</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(02)07948-5</pub-id>
          </element-citation>
        </ref>
        <ref id="bib36">
          <label>36</label>
          <element-citation publication-type="journal" id="sref36">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Welch</surname>
                <given-names>HG</given-names>
              </name>
              <name name-style="western">
                <surname>Prorok</surname>
                <given-names>PC</given-names>
              </name>
              <name name-style="western">
                <surname>O'Malley</surname>
                <given-names>AJ</given-names>
              </name>
              <name name-style="western">
                <surname>Kramer</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness</article-title>
            <source>NEJM</source>
            <volume>375</volume>
            <issue>15</issue>
            <year>2016</year>
            <fpage>1438</fpage>
            <lpage>1447</lpage>
            <pub-id pub-id-type="pmid">27732805</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1600249</pub-id>
          </element-citation>
        </ref>
        <ref id="bib37">
          <label>37</label>
          <element-citation publication-type="journal" id="sref37">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Weinstock</surname>
                <given-names>JS</given-names>
              </name>
              <name name-style="western">
                <surname>Gopakumar</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Burugula</surname>
                <given-names>BB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis</article-title>
            <source>Nature</source>
            <volume>616</volume>
            <issue>7958</issue>
            <year>2023</year>
            <fpage>755</fpage>
            <lpage>763</lpage>
            <pub-id pub-id-type="pmid">37046083</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-05806-1</pub-id>
            <pub-id pub-id-type="pmcid">PMC10360040</pub-id>
          </element-citation>
        </ref>
        <ref id="bib38">
          <label>38</label>
          <element-citation publication-type="journal" id="sref38">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pich</surname>
                <given-names>O</given-names>
              </name>
              <name name-style="western">
                <surname>Reyes-Salazar</surname>
                <given-names>I</given-names>
              </name>
              <name name-style="western">
                <surname>Gonzalez-Perez</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Lopez-Bigas</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Discovering the drivers of clonal hematopoiesis</article-title>
            <source>Nat Commun</source>
            <volume>13</volume>
            <issue>1</issue>
            <year>2022</year>
            <fpage>4267</fpage>
            <pub-id pub-id-type="pmid">35871184</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-31878-0</pub-id>
            <pub-id pub-id-type="pmcid">PMC9308779</pub-id>
          </element-citation>
        </ref>
      </ref-list>
      <sec id="appsec1" sec-type="supplementary-material">
        <title>Supplementary Material</title>
        <p id="p0185">
<supplementary-material content-type="local-data" id="ec1" position="float" orientation="portrait"><caption><title>Supplemental Figures</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BLOODA_ADV-2023-011262-mmc1.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="ec2" position="float" orientation="portrait"><caption><title>Supplemental Tables</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BLOODA_ADV-2023-011262-mmc2.xlsx" position="float" orientation="portrait"/></supplementary-material>
</p>
      </sec>
      <ack id="ack0010">
        <title>Acknowledgments</title>
        <p id="p0170">This work was supported by grants from the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008884</institution-id><institution>Edward P. Evans Foundation</institution></institution-wrap></funding-source> (A.J.S., X.W., and R.L.L.), the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source>/<funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source> P30-CA008748 (R.L.L.), K08-CA267058 (W.X.), T32-CA009207 (J.J.), and <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/100017050</institution-id><institution>Cycle for Survival</institution></institution-wrap></funding-source> (P.S.V., W.X., and R.L.L.).</p>
        <sec id="sec5">
          <title>Authorship</title>
          <p id="p0175">Contribution: A.J.S., R.N.P., B.S., W.X., M.F.B., S.M., and R.L.L. designed the research; A.J.S., S.F.-E., R.N.P., S.Y.P., J.H.M., R.H.S., A.R.B., A.S.M., and S.M. generated data; A.J.S., K.M., and R.L.L. wrote the manuscript; A.J.S., S.M.D., S.F.-E., A.R.B., A.S.M., X.W., J.J., and P.S.-V. analyzed data; and all authors read and edited the manuscript.</p>
        </sec>
      </ack>
      <fn-group>
        <fn id="d35e77">
          <label>∗</label>
          <p id="ntpara0035">A.J.S. and K.N.M. contributed equally to this work.</p>
        </fn>
        <fn id="d35e81">
          <label>†</label>
          <p id="ntpara0040">S.M. and R.L.L. contributed equally to this work.</p>
        </fn>
        <fn id="d35e85">
          <p id="ntpara0020">Deidentified CH mutation calls sufficient to reproduce the key findings of our analysis are included in <xref rid="appsec1" ref-type="sec">supplemental Data</xref>.</p>
        </fn>
        <fn id="d35e91">
          <p id="ntpara0025">Conventional CH calls are publicly available at the cBioPortal for Cancer Genomics<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cbioportal.org/study/summary?id=msk_ch_2023" id="intref0010">https://www.cbioportal.org/study/summary?id=msk_ch_2023</ext-link>. The 47 532 patients in dataset “Cancer Therapy and Clonal Hematopoiesis (MSK, Blood Adv 2023)” include all cases from the manuscript as well as additional cases that were bioinformatically evaluated but not included in the manuscript due to our data cutoff date.</p>
        </fn>
        <fn id="d35e101">
          <p id="ntpara0010">Analysis of a portion of this patient cohort was previously published.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref></p>
        </fn>
        <fn id="d35e107">
          <p id="ntpara0030">The full-text version of this article contains a data supplement.</p>
        </fn>
      </fn-group>
    </back>
  </article>
</pmc-articleset>
